CEPTARIS THERAPEUTICS
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
CEPTARIS THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2002-01-01
Address:
Malvern, Pennsylvania, United States
Country:
United States
Website Url:
http://www.ceptaris.com
Total Employee:
11+
Status:
Closed
Contact:
610-975-9290
Total Funding:
64.79 M USD
Technology used in webpage:
Cloudflare DNS CDNS Network
Similar Organizations
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
Aditum Bio
Aditum Bio is an investment fund that specializes in acquiring and developing pharmaceutical assets.
ARase Therapeutics
Arase Therapeutics is a science-focused oncology company developing therapies that modulate cancer-relevant cell signaling pathways.
MediQuest Therapeutics
MediQuest Therapeutics is a pharmaceutical company providing topical solutions for inflammatory and infectious diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Validus Cellular Therapeutics
Validus Cellular Therapeutics is a developer of therapeutic solutions for treating infectious diseases.
Wise Therapeutics
Wise Therapeutics uses breakthrough neuroscientific research to improve mental health through casual, accessible mobile games.
Current Advisors List
Current Employees Featured
Founder
Investors List
Palo Alto Investors
Palo Alto Investors investment in Series D - Ceptaris Therapeutics
BioAdvance
BioAdvance investment in Series D - Ceptaris Therapeutics
Vivo Capital
Vivo Capital investment in Series D - Ceptaris Therapeutics
Aperture Venture Partners
Aperture Venture Partners investment in Series D - Ceptaris Therapeutics
Osage Venture Partners
Osage Venture Partners investment in Series D - Ceptaris Therapeutics
Third Point Ventures
Third Point Ventures investment in Series D - Ceptaris Therapeutics
Burrill & Company
Burrill & Company investment in Series D - Ceptaris Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Ceptaris Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Ceptaris Therapeutics
Burrill & Company
Burrill & Company investment in Series D - Ceptaris Therapeutics
Official Site Inspections
http://www.ceptaris.com
- Host name: 165.150.15.20
- IP address: 165.150.15.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
